PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds […]
PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds […]